You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HIVTSQs

Showing 1 - 17 of 17
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Human Immunodeficiency Virus Type 1 (HIV-1) Trial in Worldwide (Cabotegravir Injectable Suspension, Rilpivirine Injectable

Completed
  • Human Immunodeficiency Virus Type 1 (HIV-1)
  • Cabotegravir Injectable Suspension
  • Rilpivirine Injectable Suspension
  • Bakersfield, California
  • +31 more
May 31, 2023

Human Immunodeficiency Virus Type 1 (HIV-1) Trial in Worldwide (Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine -

Active, not recruiting
  • Human Immunodeficiency Virus Type 1 (HIV-1)
  • Cabotegravir - Injectable Suspension (CAB LA)
  • Rilpivirine - Injectable Suspension (RPV LA)
  • Macon, Georgia
  • +29 more
May 31, 2023

HIV Trial in Worldwide (Cabotegravir Tablets, Cabotegravir Injectable Suspension (CAB LA), Rilpivirine Tablets)

Active, not recruiting
  • HIV Infections
  • Cabotegravir Tablets
  • +4 more
  • Bakersfield, California
  • +116 more
Jan 22, 2023

HIV, HIV Trial (Dolutegravir, Lamivudine, Bictegravir)

Not yet recruiting
  • HIV
  • HIV Infections
  • (no location specified)
Aug 4, 2023

HIV Trial (DTG/3TC, Cabotegravir (CAB) LA, Rilpivirine (RPV) LA)

Not yet recruiting
  • HIV Infections
  • (no location specified)
Jun 13, 2023

Hiv, Transgenderism Trial in Toronto (Biktarvy 50/200/25 Tab, Estradiol Tablets)

Recruiting
  • Hiv
  • Transgenderism
  • Biktarvy 50/200/25 Tab
  • Estradiol Tablets
  • Toronto, Ontario, Canada
    Maple Leaf Research
Dec 15, 2022

HIV-1-infection Trial in Verona (HIV Treatment Satisfaction Questionnaire status)

Completed
  • HIV-1-infection
  • HIV Treatment Satisfaction Questionnaire status
  • Verona, Italy
    AOUI Verona - UOC Malattie Infettive e Tropicali c/o Policlinico
Jul 28, 2021

HIV Trial in Canada, United States (CAB LA, RPV LA, RPV)

Active, not recruiting
Has Results
  • HIV Infections
  • CAB LA
  • +3 more
  • Phoenix, Arizona
  • +29 more
Jan 22, 2023

Long-acting Injectable Cabotegravir + Rilpivirine

Not yet recruiting
  • Patient Satisfaction
  • +3 more
    • Santiago, Region Metropolitana, Chile
      CICUC
    Apr 18, 2023

    Implementing Long-Acting Novel Antiretrovirals

    Recruiting
    • Human Immunodeficiency Viruses
    • The Feasibility of Intervention Measure (FIM) and Acceptability of Intervention Measure (AIM)
    • Brighton, United Kingdom
    • +5 more
    Sep 8, 2022

    HIV Trial in Worldwide (DTG 50 mg, RPV 25 mg, CAR)

    Active, not recruiting
    Has Results
    • HIV Infections
    • DTG 50 mg
    • +2 more
    • Long Beach, California
    • +64 more
    Dec 3, 2021

    HIV Trial in Worldwide (DTG 50 mg, RPV 25 mg, CAR)

    Active, not recruiting
    Has Results
    • HIV Infections
    • DTG 50 mg
    • +2 more
    • Bakersfield, California
    • +61 more
    Dec 3, 2021

    Study of Multidrug-Resistant Patient Outcomes With and Without

    Recruiting
    • HIV Infections
    • Multi-Antiviral Resistance
    • No ibalizumab or Pre-ibalizumab treatment
    • On ibalizumab treatment
    • Los Angeles, California
    • +38 more
    Jan 31, 2023

    HIV Trial in Worldwide (Cabotegravir Tablets, Rilpivirine Tablets, Cabotegravir Injectable Suspension)

    Active, not recruiting
    Has Results
    • HIV Infections
    • Cabotegravir Tablets
    • +3 more
    • Birmingham, Alabama
    • +118 more
    Jul 14, 2021

    Infection, Human Immunodeficiency Virus, HIV Trial in Worldwide (Dolutegravir/abacavir/lamivudine FDC, Atazanavir, Ritonavir)

    Active, not recruiting
    Has Results
    • Infection, Human Immunodeficiency Virus
    • HIV Infections
    • Dolutegravir/abacavir/lamivudine FDC
    • +3 more
    • Phoenix, Arizona
    • +88 more
    Feb 8, 2022

    HIV-1 Trial in United States (DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC)

    Completed
    Has Results
    • HIV-1
    • DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC
    • Phoenix, Arizona
    • +15 more
    Sep 2, 2020

    HIV-1 Infection Trial in La Roche-sur-Yon, Nantes (Abacavir/Lamivudine/Dolutegravir)

    Completed
    • HIV-1 Infection
    • La Roche-sur-Yon, France
    • +1 more
    Feb 19, 2016